Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Deepu Madduri"'
Autor:
Nikhil Munshi, Tom Martin, Saad Z Usmani, Jesus Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, Abhinav Deol, Myo Htut, Alexander Lesokhin, Yi Lin, Elizabeth O’donnell, Carolyn C Jackson, Tzu-Min Yeh, Arnob Banerjee, Enrique Zudaire, Deepu Madduri, Christopher Delcorral, Lida Pacaud, Sundar Jagannath
Publikováno v:
HemaSphere, Vol 7, p e6102468 (2023)
Externí odkaz:
https://doaj.org/article/0953a89f5cd849b38cfb3f30eba6c672
Autor:
Martin Vogel, Muna Qayed, Shanmuganathan Chandrakasan, Sharmila Raghunandan, Melinda Pauly, William G Blum, Madhav V Dhodapkar, Mohamed Elkhalifa, Benjamin Watkins, Michelle Schoettler, Edwin Horwitz, Suhag Parikh, Kathryn Leung, Elyse Bryson, Laura Deeb, Jonathan L Kaufman, Diana Worthington-White, Adina Alazraki, Jordan M Schecter, Deepu Madduri, Carolyn C Jackson, Enrique Zudaire, Agne Taraseviciute-Morris, Alexander Babich, Tonia Nesheiwat, Nikoletta Lendvai, Lida Pacaud, Kirsten M Williams
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
Plasmablastic lymphoma (PBL) is a rare subtype of aggressive large B-cell lymphoma, with a dismal prognosis despite aggressive therapies. New approaches are needed for those with refractory disease. PBL expresses antigens similar to multiple myeloma
Externí odkaz:
https://doaj.org/article/8d09210335ff4eafb1dab8feacb96d23
Autor:
Adam D. Cohen, Samir Parekh, Bianca D. Santomasso, Jaime Gállego Pérez-Larraya, Niels W. C. J. van de Donk, Bertrand Arnulf, Maria-Victoria Mateos, Nikoletta Lendvai, Carolyn C. Jackson, Kevin C. De Braganca, Jordan M. Schecter, Loreta Marquez, Erin Lee, Ingrid Cornax, Enrique Zudaire, Claire Li, Yunsi Olyslager, Deepu Madduri, Helen Varsos, Lida Pacaud, Muhammad Akram, Dong Geng, Andrzej Jakubowiak, Hermann Einsele, Sundar Jagannath
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 2, Pp 1-9 (2022)
Abstract Chimeric antigen receptor (CAR) T-cell therapies are highly effective for multiple myeloma (MM) but their impressive efficacy is associated with treatment-related neurotoxicities in some patients. In CARTITUDE-1, 5% of patients with MM repor
Externí odkaz:
https://doaj.org/article/c52ccfe861b6431796f476020b355a8d
Autor:
Bo Wang, Oliver Van Oekelen, Tarek H. Mouhieddine, Diane Marie Del Valle, Joshua Richter, Hearn Jay Cho, Shambavi Richard, Ajai Chari, Sacha Gnjatic, Miriam Merad, Sundar Jagannath, Samir Parekh, Deepu Madduri
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2020)
Abstract Background The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths in the USA. Our institution has treated over 2000 COVID-19 patients during the pandemic in New York City. The pandemic directly impacted cancer
Externí odkaz:
https://doaj.org/article/2a8a134dee804d76a7bfadb029e72a2b
Autor:
Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard, Lowena Tam, Daniel Verina, Ajai Chari
Publikováno v:
Therapeutic Advances in Hematology, Vol 12 (2021)
Daratumumab, a human immunoglobulin G1 kappa monoclonal antibody that targets CD38, is currently approved as monotherapy and in varying combinations with approved anti-myeloma regimens in both newly diagnosed multiple myeloma and relapsed refractory
Externí odkaz:
https://doaj.org/article/f0d2ae2c53d94f1dac01e92186e550a8
Publikováno v:
Therapeutic Advances in Hematology, Vol 12 (2021)
Outcomes of patients with multiple myeloma (MM) who become refractory to standard therapies are particularly poor and novel agents are greatly needed to improve outcomes in such patients. B-cell maturation antigen (BCMA) has become an important thera
Externí odkaz:
https://doaj.org/article/d78ef0342e26469095585ae9953d6d45
Publikováno v:
Therapeutic Advances in Hematology, Vol 11 (2020)
Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite significant advances over the past decade, with the advent of multiple new classes of anti-myeloma agents, including immunomodulatory drugs, proteasome inhibitors and monoc
Externí odkaz:
https://doaj.org/article/bfcb205c85d740478ce3085a48493870
Autor:
Guido Lancman, Suzanne Arinsburg, Jeffrey Jhang, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Joshua Richter, Ajai Chari
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Daratumumab has proven to be highly efficacious for relapsed and refractory multiple myeloma (MM) and has recently been approved in the frontline setting for MM patients ineligible for transplantation. In the future, expanded indications are possible
Externí odkaz:
https://doaj.org/article/f1862f99193e4a52bca5a26f7bcbe472
Autor:
Thomas Martin, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej Jakubowiak, Yi Lin, Sundar Jagannath
Publikováno v:
Journal of Clinical Oncology. 41:1265-1274
PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, and durable responses at 12 months. He
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 23:22-27
Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized the treatment paradigm for heavily pretreated B-cell malignancies such as large B-cell lymphoma. There is a major unmet need for effective treatments for heavily pretreated relaps